Technion technology behind revolutionary new device
“Patients receiving oncology therapies are immuno-compromised and susceptible to infection,” says Dr. Avishay Bransky, CEO of PixCell Medical. “A hospital environment presents a major risk, due to potential contact with other patients, staff and for hospital-acquired infection. As such, we believe that enabling the shift to home care settings for oncology, in particular, is a crucial evolution in cancer care.”
PixCell Medical offers a new technology that enables rapid, at home blood tests that could enable remote the administration of remote chemotherapy treatment for cancer patients. Their patent-protected device uses an underlying technology known as viscoelastic focusing (VEF), which was first discovered at the Technion–Israel Institute of Technology.